Galina Selivanova
Professor, Senior
E-mail: galina.selivanova@ki.se
Telephone: +46852486302
Visiting address: Solnavägen 9, B7, 17165 Solna
Postal address: C1 Mikrobiologi, tumör- och cellbiologi, C1 Tumor Biology Wilhelm, 171 77 Stockholm
Part of:
About me
- Galina Selivanova is a Professor of Cell and Tumor Biology and one of the pioneers in research on p53 – a protein with a central role in the protection against cancer.
Articles
- Article: BRITISH JOURNAL OF CANCER. 2022;127(11):2060-2071Zhou X; Santos GS; Zhan Y; Oliveira MMS; Rezaei S; Singh M; Peuget S; Westerberg LS; Johnsen JI; Selivanova G
- Article: MOLECULAR CANCER THERAPEUTICS. 2022;21(10):1524-1534Zhan Y; Zhou X; Peuget S; Singh M; Peyser BD; Fan Z; Selivanova G
- Article: FRONTIERS IN MOLECULAR BIOSCIENCES. 2022;9:823195Grinkevich VV; Vema A; Fawkner K; Issaeva N; Andreotti V; Dickinson ER; Hedstrom E; Spinnler C; Inga A; Larsson L-G; Karlen A; Wilhelm M; Barran PE; Okorokov AL; Selivanova G; Zawacka-Pankau JE
- Article: ONCOGENE. 2022;41(15):2173-2186Aschtgen M-S; Fragkoulis K; Sanz G; Normark S; Selivanova G; Henriques-Normark B; Peuget S
- Article: CANCER DISCOVERY. 2021;11(12):3090-3105Zhou X; Singh M; Santos GS; Guerlavais V; Carvajal LA; Aivado M; Zhan Y; Oliveira MMS; Westerberg LS; Annis DA; Johnsen JI; Selivanova G
- Journal article: CLINICAL CANCER RESEARCH. 2021;27(17):4943Burmakin M; Shi Y; Hedström E; Kogner P; Selivanova G
- Article: ISCIENCE. 2020;23(12):101785Guerrero-Garzon JF; Madland E; Zehl M; Singh M; Rezaei S; Aachmann FL; Courtade G; Urban E; Rueckert C; Busche T; Kalinowski J; Cao Y-R; Jiang Y; Jiang C-L; Selivanova G; Zotchev SB
- Article: BREAST CANCER RESEARCH. 2020;22(1):80Singh M; Zhou X; Chen X; Santos GS; Peuget S; Cheng Q; Rihani A; Arner ESJ; Hartman J; Selivanova G
- Article: CANCER RESEARCH. 2020;80(7):1538-1550Peuget S; Zhu J; Sanz G; Singh M; Gaetani M; Chen X; Shi Y; Saei AA; Visnes T; Lindstrom MS; Rihani A; Moyano-Galceran L; Carlson JW; Hjerpe E; Joneborg U; Lehti K; Hartman J; Helleday T; Zubarev R; Selivanova G
- Article: JOURNAL OF CLINICAL MEDICINE. 2020;9(2):E598-598Rangel-Pozzo A; Booth S; Yu PLI; Singh M; Selivanova G; Mai S
- Article: SCIENTIFIC REPORTS. 2020;10(1):1049Zhu J; Singh M; Selivanova G; Peuget S
- Article: HAEMATOLOGICA. 2020;105(1):170-181Demir S; Boldrin E; Sun Q; Hampp S; Tausch E; Eckert C; Ebinger M; Handgretinger R; te Kronnie G; Wiesmueller L; Stilgenbauer S; Selivanova G; Debatin K-M; Meyer LH
- Article: CELL DEATH & DISEASE. 2019;10(11):845Ristau J; van Hoef V; Peuget S; Zhu J; Guan B-J; Liang S; Hatzoglou M; Topisirovic I; Selivanova G; Larsson O
- Article: SCIENTIFIC REPORTS. 2019;9(1):2379Prediction of response to anti-cancer drugs becomes robust via network integration of molecular dataFranco M; Jeggari A; Peuget S; Bottger F; Selivanova G; Alexeyenko A
- Article: CANCER LETTERS. 2019;442:341-350Azatyan A; Gallo-Oller G; Diao Y; Selivanova G; Johnsen JI; Zaphiropoulos PG
- Article: CELL CYCLE. 2018;17(24):2697-2715Zhang F; Zakaria SM; Tabor VH; Singh M; Tronnersjo S; Goodwin J; Selivanova G; Bartek J; Castell A; Larsson L-G
- Journal article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2017;292(48):19607Bykov VJN; Issaeva N; Zache N; Shilov A; Hultcrantz M; Bergman J; Selivanova G; Wiman KG
- Journal article: KLINISCHE PADIATRIE. 2016;228(03)Demir S; Selivanova G; Tausch E; Wiesmüller L; Stilgenbauer S; te Kronnie G; Debatin K; Meyer L
- Article: FRONTIERS IN MOLECULAR BIOSCIENCES. 2015;2:39Dickinson ER; Jurneczko E; Nicholson J; Hupp TR; Zawacka-Pankau J; Selivanova G; Barran PE
- Article: CELL DEATH & DISEASE. 2015;6(1):e1616Xu J; Eriksson SE; Cebula M; Sandalova T; Hedstrom E; Pader I; Cheng Q; Myers CR; Antholine WE; Nagy P; Hellman U; Selivanova G; Lindqvist Y; Arner ESJ
- Article: CARCINOGENESIS. 2014;35(10):2273-2282Ireno IC; Wiehe RS; Stahl AI; Hampp S; Aydin S; Troester MA; Selivanova G; Wiesmueller L
- Article: CELL DEATH AND DIFFERENTIATION. 2014;21(9):1493-1502Li H; Zhang Y; Stroese A; Tedesco D; Gurova K; Selivanova G
- Article: CELL DEATH AND DIFFERENTIATION. 2014;21(4):612-623Shi Y; Nikulenkov F; Zawacka-Pankau J; Li H; Gabdoulline R; Xu J; Eriksson S; Hedstroem E; Issaeva N; Kel A; Arner ESJ; Selivanova G
- Article: CELL DEATH & DISEASE. 2013;4(10):e881Peng X; Zhang M-Q; Conserva F; Hosny G; Selivanova G; Bykov VJN; Arner ESJ; Wiman KG
- Article: CLINICAL CANCER RESEARCH. 2013;19(18):5092-5103Burmakin M; Shi Y; Hedstrom E; Kogner P; Selivanova G
- Article: CELL DEATH AND DIFFERENTIATION. 2012;19(12):1992-2002Nikulenkov F; Spinnler C; Li H; Tonelli C; Shi Y; Turunen M; Kivioja T; Ignatiev I; Kel A; Taipale J; Selivanova G
- Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2012;287(35):29336-29347Smith SD; Enge M; Bao W; Thullberg M; Costa TDF; Olofsson H; Gashi B; Selivanova G; Stromblad S
- Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2011;286(48):41600-41615Zawacka-Pankau J; Grinkevich VV; Huenten S; Nikulenkov F; Gluch A; Li H; Enge M; Kel A; Selivanova G
- Article: CELL DEATH AND DIFFERENTIATION. 2011;18(11):1736-1745Spinnler C; Hedstrom E; Li H; de Lange J; Nikulenkov F; Teunisse AFAS; Verlaan-de Vries M; Grinkevich V; Jochemsen AG; Selivanova G
- Article: CELL CYCLE. 2011;10(19):3346-3358Li H; Lakshmikanth T; Garofalo C; Enge M; Spinnler C; Anichini A; Szekely L; Karre K; Carbone E; Selivanova G
- Article: CLINICAL CANCER RESEARCH. 2011;17(9):2830-2841Zandi R; Selivanova G; Christensen CL; Gerds TA; Willumsen BM; Poulsen HS
- Article: CELL CYCLE. 2011;10(2):301-307Bao W; Chen M; Zhao X; Kumar R; Spinnler C; Thullberg M; Issaeva N; Selivanova G; Stromblad S
- Article: CELL CYCLE. 2010;9(9):1847-1855Zhao CY; Grinkevich VV; Nikulenkov F; Bao W; Selivanova G
- Article: CANCER RESEARCH. 2010;70(8):3372-3381Zhao CY; Szekely L; Bao W; Selivanova G
- Article: CELL CYCLE. 2009;8(21):3584-3591Hedstrom E; Eriksson S; Zawacka-Pankau J; Arner ESJ; Selivanova G
- Article: CANCER RESEARCH. 2009;69(15):6241-6248Rinaldo C; Prodosmo A; Siepi F; Moncada A; Sacchi A; Selivanova G; Soddu S
- Journal article: CANCER CELL. 2009;16(1):79Enge M; Bao W; Hedström E; Jackson SP; Moumen A; Selivanova G
- Article: CANCER CELL. 2009;15(5):441-453Grinkevich VV; Nikulenkov F; Shi Y; Enge M; Bao W; Maljukova A; Gluch A; Kel A; Sangfelt O; Selivanova G
- Article: CANCER CELL. 2009;15(3):171-183Enge M; Bao W; Hedstrom E; Jackson SP; Moumen A; Selivanova G
- Article: EXPERIMENTAL CELL RESEARCH. 2009;315(3):451-461Hedstrom E; Issaeva N; Enge M; Selivanova G
- Journal article: APMIS. 2008;116(5):434-435Zandi R; Selivanova G; Poulsen HS
- Journal article: APMIS. 2008;116(5):434-435Zandi R; Selivanova G; Poulsen HS
- Article: BRITISH JOURNAL OF HAEMATOLOGY. 2008;141(4):445-453Nahi H; Selivanova G; Lehmann S; Mollgard L; Bengtzen S; Concha H; Svensson A; Wiman KG; Merup M; Paul C
- Article: EUROPEAN JOURNAL OF CANCER. 2007;43(12):1877-1882Pak F; Mwakigonja AR; Kokhaei P; Hosseinzadeh N; Pyakurel P; Kaaya E; Bogdanovic G; Selivanova G; Biberfeld P
- Article: CELL DEATH AND DIFFERENTIATION. 2007;14(3):411-421Liu T; Laurell C; Selivanova G; Lundeberg J; Nilsson P; Wiman KG
- Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2007;282(4):2466-2472Zawacka-Pankau J; Issaeva N; Hossain S; Pramanik A; Selivanova G; Podhajska AJ
- Article: EMBO JOURNAL. 2006;25(21):5191-5200Okorokov AL; Sherman MB; Plisson C; Grinkevich V; Sigmundsson K; Selivanova G; Milner J; Orlova EV
- Article: APOPTOSIS. 2006;11(2):221-233Hallgren O; Gustafsson L; Irjala H; Selivanova G; Orrenius S; Svanborg C
- Article: BRITISH JOURNAL OF HAEMATOLOGY. 2006;132(2):230-236Nahi H; Merup M; Lehmann S; Bengtzen S; Möllgård L; Selivanova G; Wiman KG; Paul C
- Journal article: BLOOD. 2005;106(11):5536Nahi H; Merup M; Möllgård L; Selivanova G; Paul C
- Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2005;280(34):30384-30391Bykov VJN; Issaeva N; Zache N; Shilov A; Hultcrantz M; Bergman J; Selivanova G; Wiman KG
- Article: ONCOGENE. 2005;24(21):3484-3491Bykov VJN; Zache N; Stridh H; Westman J; Bergman J; Selivanova G; Wiman KG
- Article: INTERNATIONAL JOURNAL OF RADIATION BIOLOGY. 2005;81(2):125-138Torudd J; Protopopova M; Sarimov R; Nygren J; Eriksson S; Marková E; Chovanec M; Selivanova G; Belyaev IY
- Article: JOURNAL OF CUTANEOUS PATHOLOGY. 2005;32(1):21-27Pak F; Pyakural P; Kokhaei P; Kaaya E; Pourfathollah AA; Selivanova G; Biberfeld P
- Article: NATURE MEDICINE. 2004;10(12):1321-1328Issaeva N; Bozko P; Enge M; Protopopova M; Verhoef LGGC; Masucci M; Pramanik A; Selivanova G
- Article: BRITISH JOURNAL OF HAEMATOLOGY. 2004;127(3):285-291Nahi H; Lehmann S; Mollgard L; Bengtzen S; Selivanova G; Wiman KG; Paul C; Merup M
- Journal article: EUROPEAN JOURNAL OF CANCER, SUPPLEMENT. 2004;2(8):62Wiman K; Bykov V; Issaeva N; Zache N; Bergman J; Selivanova G
- Article: DISCOVERY MEDICINE. 2004;4(20):28-30Selivanova G; Fersht A
- Article: CELL CYCLE. 2003;2(6):592-595Protopopova M; Selivanova G
- Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2003;100(23):13303-13307Issaeva N; Friedler A; Bozko P; Wiman KG; Fersht AR; Selivanova G
- Article: EUROPEAN JOURNAL OF CANCER. 2003;39(13):1828-1834Bykov VJN; Selivanova G; Wiman KG
- Article: CARCINOGENESIS. 2002;23(12):2011-2018Bykov VJN; Issaeva N; Selivanova G; Wiman KG
- Article: ONCOGENE. 2002;21(14):2119-2129Rippin TM; Bykov VJN; Freund SMV; Selivanova G; Wiman KG; Fersht AR
- Article: NATURE MEDICINE. 2002;8(3):282-288Bykov VJN; Issaeva N; Shilov A; Hultcrantz M; Pugacheva E; Chumakov P; Bergman J; Wiman KG; Selivanova G
- Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2002;99(3):1532-1537Heessen S; Leonchiks A; Issaeva N; Sharipo A; Selivanova G; Masucci MG; Dantuma NP
- Article: METHODS IN MOLECULAR BIOLOGY. 2002;203:279-288Selivanova G
- Article: ONCOGENE. 2001;20(39):5503-5510Falck J; Lukas C; Protopopova M; Lukas J; Selivanova G; Bartek J
- Article: JOURNAL OF BIOLOGICAL CHEMISTRY. 2001;276(25):22699-22708Grigorian M; Andresen S; Tulchinsky E; Kriajevska M; Carlberg C; Kruse C; Cohn M; Ambartsumian N; Christensen A; Selivanova G; Lukanidin E
- Journal article: EUROPEAN JOURNAL OF CANCER. 2001;37:s139Wiman KG; Bykov VJ; Issaeva N; Shilov A; Bergman J; Selivanova G
- Article: APOPTOSIS. 2001;6(1-2):133-137Henriksson M; Selivanova G; Lindström M; Wiman KG
- Article: ONCOGENE. 2000;19(45):5123-5133Xu DW; Wang Q; Gruber A; Björkholm M; Chen ZG; Zaid A; Selivanova G; Peterson C; Wiman KG; Pisa P
- Article: NUCLEIC ACIDS RESEARCH. 2000;28(20):4005-4012Zotchev SB; Protopopova M; Selivanova G
- Article: BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. 1999;265(1):1-6Asker C; Wiman KG; Selivanova G
- Article: MOLECULAR AND CELLULAR BIOLOGY. 1999;19(5):3395-3402Selivanova G; Ryabchenko L; Jansson E; Iotsova V; Wiman KG
- Article: SEMINARS IN CANCER BIOLOGY. 1998;8(5):369-378Selivanova G; Kawasaki T; Ryabchenko L; Wiman KG
- Article: NATURE MEDICINE. 1997;3(6):632-638Selivanova G; Iotsova V; Okan I; Fritsche M; Strom M; Groner B; Grafstrom RC; Wiman KG
- Article: NUCLEIC ACIDS RESEARCH. 1996;24(18):3560-3567Selivanova G; Iotsova V; Kiseleva E; Strom M; Bakalkin G; Grafstrom RC; Wiman KG
- Article: NUCLEIC ACIDS RESEARCH. 1995;23(3):362-369BAKALKIN G; SELIVANOVA G; YAKOVLEVA T; KISELEVA E; KASHUBA E; MAGNUSSON KP; SZEKELY L; KLEIN G; TERENIUS L; WIMAN KG
- Journal article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 1994;91(1):413-417BAKALKIN G; YAKOVLEVA T; SELIVANOVA G; MAGNUSSON KP; SZEKELY L; KISELEVA E; KLEIN G; TERENIUS L; WIMAN KG
- Journal article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 1993;90(12):5455-5459SZEKELY L; SELIVANOVA G; MAGNUSSON KP; KLEIN G; WIMAN KG
- Journal article: RUSSIAN JOURNAL OF GENETICS. 1992;28(5):66-72PLOTNIKOVA TG; SELIVANOVA GN; JOMANTAS JV; KOZLOV YI
- Show more
All other publications
- Review: NATURE REVIEWS CANCER. 2024;24(3):192-215Peuget S; Zhou X; Selivanova G
- Editorial comment: CANCER DISCOVERY. 2023;13(5):1043-1045Peuget S; Selivanova G
- Conference publication: CANCER SCIENCE. 2023;114:249Selivanova G; Zhou X; Singh M; Sanz G; Guerlavais V; Carvajal LA; Aivado M; Annis A; Zhan Y; Oliveira M; Westerberg L; Johnsen JI
- Preprint: BIORXIV. 2021Grinkevich V; Aparna V; Fawkner K; Issaeva N; Andreotti V; Dickinson E; Hedström E; Spinnler C; Inga A; Larsson L-G; Karlén A; Wilhelm M; Barran P; Okorokov A; Selivanova G; Zawacka-Pankau J
- Editorial comment: CANCERS. 2021;13(19):4850Peuget S; Selivanova G
- Review: JOURNAL OF MOLECULAR CELL BIOLOGY. 2019;11(7):586-599Sanz G; Singh M; Peuget S; Selivanova G
- Preprint: BIORXIV. 2018Zawacka-Pankau J; Grinkevich V; Burmakin M; Vema A; Fawkner K; Issaeva N; Andreotti V; Dickinson E; Hedström E; Spinnler C; Inga A; Larsson L-G; Karlén A; Tarasova O; Poroikov V; Lavrenov S; Preobrazhenskaya M; Barran P; Okorokov A; Selivanova G
- Preprint: BIORXIV. 2018Franco M; Jeggari A; Peuget S; Böttger F; Selivanova G; Alexeyenko A
- Preprint: SSRN ELECTRONIC JOURNAL. 2018Zawacka-Pankau J; Grinkevich VV; Burmakin M; Vema A; Ridderstråle K; Issaeva N; Andreotti V; Dickinson ER; Hedström E; Spinnler C; Inga A; Larsson L-G; Karlén A; Tarasova O; Poroikov V; Lavrenov S; Preobrazhenskaya M; Wilhelm M; Barran PE; Okorokov AL; Selivanova G
- Conference publication: PEDIATRIC BLOOD & CANCER. 2017;64:S70Demir S; Sun Q; Tausch E; Stilgenbauer S; te Kronnie G; Eckert C; Wiesmueller L; Selivanova G; Debatin KM; Meyer L
- Corrigendum: CANCER CELL. 2017;31(5):724-726Grinkevich VV; Nikulenkov F; Shi Y; Enge M; Bao W; Maljukova A; Gluch A; Kel A; Sangfelt O; Selivanova G
- Corrigendum: CELL DEATH & DISEASE. 2017;8(4):e2751Peng X; Zhang M-Q; Conserva F; Hosny G; Selivanova G; Bykov VJN; Arner ESJ; Wiman KG
- Conference publication: ANNALS OF HEMATOLOGY. 2017;96:S73Demir S; Sun Q; Tausch E; Stilgenbauer S; Kronnie GT; Wiesmueller L; Selivanova G; Debatin K-M; Meyer LH
- Conference publication: ONCOLOGY RESEARCH AND TREATMENT. 2016;39:200Demir S; Selivanova G; Tausch E; Wiesmueller L; Stilgenbauer S; te Kronnie G; Debatin K-M; Meyer LH
- Conference publication: HAEMATOLOGICA. 2016;101:28Demir S; Selivanova G; Tausch E; Wiesmueller L; Stilgenbauer S; te Kronnie G; Debatin KM; Meyer LH
- Conference publication: ONCOLOGY RESEARCH AND TREATMENT. 2016;39:117Demir S; Selivanova G; Tausch E; Wiesmueller L; Stilgenbauer S; te Kronnie G; Debatin K-M; Meyer L
- Conference publication: BLOOD. 2015;126(23):903Demir S; Selivanova G; Tausch E; Wiesmueller L; Stilgenbauer S; Te Kronnie G; Debatin K-M; Meyer LH
- Conference publication: PEDIATRIC BLOOD & CANCER. 2015;62:S332Milosevic J; Treis D; Malin M; Fransson S; Sveinbjornsson B; Eissler N; Baryawno N; Tanino K; Selivanova G; Sakaguchi K; Martinsson T; Johnsen JI; Kogner P
- Conference publication: CANCER RESEARCH. 2015;75:503Miloseyic J; Treis D; Wickstrom M; Fransson S; Eissler N; Syeinbjornsson B; Baryawno N; Tanino K; Selivanova G; Sakaguchi K; Martinsson T; Johnsen JI; Kogner P
- Review: JOURNAL OF INTERNAL MEDICINE. 2015;277(2):248-259Zawacka-Pankau J; Selivanova G
- Review: FEBS LETTERS. 2014;588(16):2628-2638Selivanova G
- Book chapter: P53 IN THE CLINICS. 2013;p. 231-255Grinkevich VV; Warnecke A; Selivanova G
- Editorial comment: ONCOIMMUNOLOGY. 2012;1(4):541-543Li H; Lakshmikanth T; Carbone E; Selivanova G
- Review: SEMINARS IN CANCER BIOLOGY. 2010;20(1):46-56Selivanova G
- Editorial comment: CELL. 2009;139(7):1220-1222Selivanova G; Ivaska J
- Conference publication: JOURNAL OF THORACIC ONCOLOGY. 2009;4(9):S592-S593Zandi R; Selivanova G; Willumsen BM; Poulsen HS
- Conference publication: CANCER RESEARCH. 2009;69Zandi R; Selivanova G; Willumsen B; Poulsen H
- Review: TOXICOLOGY AND APPLIED PHARMACOLOGY. 2008;232(3):487-497Zawacka-Pankau J; Krachulec J; Grulkowski I; Bielawski KP; Selivanova G
- Conference publication: APMIS. 2008;116(5):434-435Zandi R; Selivanova G; Poulsen HS
- Review: ONCOGENE. 2007;26(15):2243-2254Selivanova G; Wiman KG
- Book chapter: 25 YEARS OF P53 RESEARCH. 2007;p. 399-419Selivanova G; Bykov VJN; Wiman KG
- Conference publication: ACTA PHARMACOLOGICA SINICA. 2006;27:412-413Liu T; Laurell C; Selivanova G; Lundeberg J; Nilson P; Wiman KG
- Book chapter: APOPTOSIS AND CANCER THERAPY. 2006;p. 891-912Stridh H; Bykov VJN; Selivanova G; Wiman KG
- Conference publication: BLOOD. 2005;106(11):472BNahi H; Merup M; Möllgård L; Selivanova G; Paul C
- Letter: NATURE MEDICINE. 2005;11(11):1136-1137Grinkevich V; Issaeva N; Hossain S; Pramanik A; Selivanova G
- Published conference paper: BIOELECTROMAGNETICS. 2005;26(3):173-184Belyaev IY; Hillert L; Protopopova M; Tamm C; Malmgren LOG; Persson BRR; Selivanova G; Harms-Ringdahl M
- Conference publication: ANNALS OF ONCOLOGY. 2005;16:23-24Wiman KG; Stridh H; Zache N; Rökaeus N; Issaeva N; Hammarsund M; Shen JF; Bergman J; Westman J; Selivanova G; Bykov VJN
- Book chapter: TRANSCRIPTION FACTORS: HANDBOOK OF EXPERIMENTAL PHARMACOLOGY. 2004;p. 209-258Asker C; Bykov VJN; Mendez-Vidal C; Selivanova G; Wilhelm MT; Wiman KG
- Conference publication: CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION. 2002;11(10):1227S-1228SProtopopova M; Selivanova G
- Book chapter: TUMOR SUPPRESSING VIRUSES, GENES, AND DRUGS. 2002;p. 397-415Selivanova G; Wiman KG
- Conference publication: CLINICAL CANCER RESEARCH. 2001;7(11):3792SIssaeva N; Shilov A; Bykov V; Wiman K; Selivanova G
- Conference publication: CLINICAL CANCER RESEARCH. 2001;7(11):3749SBykov VJ; Issaeva N; Shilov A; Bergman J; Selivanova G; Wiman KG
- Review: CURRENT OPINION IN INVESTIGATIONAL DRUGS. 2001;2(8):1136-1141Selivanova G
- Other: ONCOGENE. 1995;10(9):1869-1874SZEKELY L; POKROVSKAJA K; JIANG WQ; SELIVANOVA G; LOWBEER M; RINGERTZ N; WIMAN KG; KLEIN G
- Conference publication: JOURNAL OF CELLULAR BIOCHEMISTRY. 1995;:325SELIVANOVA G; BAKALKIN G; YAKOVLEVA T; KISELEVA E; SZEKELY L; TERENIUS L; WIMAN KG
- Conference publication: JOURNAL OF CELLULAR BIOCHEMISTRY. 1995;:77SELIVANOVA G; BAKALKIN G; YAKOVLEVA T; KISELEVA E; SZEKELY L; TERENIUS L; WIMAN KG
- Review: MECHANISMS AND THERAPY OF LIVER CANCER. 1995;66:143-180SELIVANOVA G; WIMAN KG
- Conference publication: JOURNAL OF CELLULAR BIOCHEMISTRY. 1994;:181SELIVANOVA G; BAKALKIN G; YAKOVLEVA T; MAGNUSSON KP; SZEKELY L; KISELEVA E; KLEIN G; TERENIUS L; WIMAN KG
- Show more
Grants
- Swedish Research Council1 January 2020 - 31 December 2023
- To tame p53 and have a long cancer-free life, continuedSwedish Cancer Society1 January 2018Despite the use of intensive multimodal therapy, metastatic cancer often leads to fatal clinical outcomes. There is a strong need to develop new targeted strategies that inhibit molecules that are important for the development of the tumor. p53 acts as "guardian of the genome", "the guardian of the genome", because of its ability to cause tumor cells to suicide. Because of this property of p53, it is inactivated in the majority of human tumors. Animal model studies have shown that restoration of p53 activity in established tumors leads to their regression. Therefore, p53 is an excellent target for anti-cancer agents. Mutant p53-reactivating molecule APR-246 is currently being tested in Phase Ib / II clinical trials in 8 countries in Europe, the US and Australia, including PiSARRO ovarian cancer trials. We need to better understand which specific molecular mechanisms, in addition to mutant p53, give sensitivity or resistance to this treatment if we are to handle cancer effectively. The main task of P53 is to activate a cellular program that leads to cell death. In our laboratory, we have shown that p53 can also inhibit carcinogenic oncogenes, which cancer cells depend on. But we know very little about the mechanism behind this. Explanation of these mechanisms will enable the development of better strategies for the clinical use of drugs that reactivate p53 and stratification of patients. Our research will also contribute to the development of new prognostic and predictive parameters that improve conventional cancer treatment. Our ambition is to create a clinically relevant model to facilitate the stratification of patients responding to APR-246-based mutant p53 directional therapy, to detect predictive biomarkers and to identify drug combinations for effective treatment and overcoming resistance.
- To tame p53 to live longer without cancerSwedish Cancer Society1 January 2017Despite intensive multimodal therapy, metastatic cancer often leads to a fatal clinical outcome. There is a strong need to develop new targeted strategies that inhibit molecules are important for tumor progression. p53 acts as the "guardian of the genome" due to its ability to prevent tumors. Therefore, p53 is a good target for anti-cancer drugs: if we use substances that restore its activity, it will cause tumors to decrease. p53's primary function is to activate a cellular program that leads to cell death. When p53 detects that a cell is damaged and can become a tumor cell, it produces signals that cause the cell to destroy itself. In our laboratory, we have shown that p53 can also suppress the cell's survival program in the tumor, and that this is crucial for its function. But we know very little about the mechanism behind this. In order to effectively use substances that restore p53's function and treat cancer, we must understand the molecular mechanism, that is, exactly how p53 prevents cancer cells from surviving. Our research aims to develop better strategies for the clinical use of substances that reactivate p53. Identification of new factors that are important for p53's function will lead to new targets for anti-cancer drugs. Our research will also contribute to the development of new prognostic and predictive parameters to improve conventional cancer treatment.
- To tame p53 to live longer without cancerSwedish Cancer Society1 January 2016Despite intensive multimodal therapy, metastatic cancer often leads to a fatal clinical outcome. There is a strong need to develop new targeted strategies that inhibit molecules are important for tumor progression. p53 acts as the "guardian of the genome" due to its ability to prevent tumors. Therefore, p53 is a good target for anti-cancer drugs: if we use substances that restore its activity, it will cause tumors to decrease. p53's primary function is to activate a cellular program that leads to cell death. When p53 detects that a cell is damaged and can become a tumor cell, it produces signals that cause the cell to destroy itself. In our laboratory, we have shown that p53 can also suppress the cell's survival program in the tumor, and that this is crucial for its function. But we know very little about the mechanism behind this. In order to effectively use substances that restore p53's function and treat cancer, we must understand the molecular mechanism, that is, exactly how p53 prevents cancer cells from surviving. Our research aims to develop better strategies for the clinical use of substances that reactivate p53. Identification of new factors that are important for p53's function will lead to new targets for anti-cancer drugs. Our research will also contribute to the development of new prognostic and predictive parameters to improve conventional cancer treatment.
- Swedish Research Council1 January 2016 - 31 December 2019
- To tame p53 to live longer without cancerSwedish Cancer Society1 January 2015Despite intensive multimodal therapy, metastatic cancer often leads to a fatal clinical outcome. There is a strong need to develop new targeted strategies that inhibit molecules are important for tumor progression. p53 acts as the "guardian of the genome" due to its ability to prevent tumors. Therefore, p53 is a good target for anti-cancer drugs: if we use substances that restore its activity, it will cause tumors to decrease. p53's primary function is to activate a cellular program that leads to cell death. When p53 detects that a cell is damaged and can become a tumor cell, it produces signals that cause the cell to destroy itself. In our laboratory, we have shown that p53 can also suppress the cell's survival program in the tumor, and that this is crucial for its function. But we know very little about the mechanism behind this. In order to effectively use substances that restore p53's function and treat cancer, we must understand the molecular mechanism, that is, exactly how p53 prevents cancer cells from surviving. Our research aims to develop better strategies for the clinical use of substances that reactivate p53. Identification of new factors that are important for p53's function will lead to new targets for anti-cancer drugs. Our research will also contribute to the development of new prognostic and predictive parameters to improve conventional cancer treatment.
- To target p53 networks to fight cancer: from the lab bank to the hospitalSwedish Cancer Society1 January 2014The key to successful cancer treatment is to develop drugs that specifically target important proteins in cancer. The p53 protein is a powerful naturally occurring tumor suppressor that counteracts tumor emergence by programmed cell death (apoptosis). More than 50% of all tumors carry a mutated TP53 gene. In tumors without TP53 mutation, the p53 protein is inactivated due to its accelerated degradation of MDM2. By screening small molecule libraries that can inhibit tumor growth, we have found two substances: PRIMA-1MET / Apr-246 is selective for tumor cells that express mutated p53, and RITA is selective for non-mutated p53 Many genes play a role in the onset of cancer, requiring a cancer treatment to attack multiple targets to ensure that the treatment is successful and to prevent resistance. This project is aimed at identifying new target proteins for combined treatments and developing substances that can counteract two important oncogenes simultaneously. These should also interact with PRIMA-1MET and RITA which reactivate p53. This will reduce the risk of patients developing resistance to cancer drugs. To achieve these goals we will use modern molecular and cell biological methods as well as system biology. The vision is to create new tumor-specific drugs and find drugs that can interact with each other, which will mean that our results can be used more quickly in the healthcare sector and benefit both patients and society.
- Knut and Alice Wallenberg Foundation1 January 2013 - 1 January 2018
- Rational design of synergistic combinations of target-specific anti-cancer drugsRagnar Söderberg Foundation1 January 2012 - 31 December 2014
- Swedish Research Council1 January 2011 - 31 December 2015
Employments
- Professor, Senior, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 2025-2026
- Professor, Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, 2010-2025
Degrees and Education
- Docent, Karolinska Institutet, 2002